US EditionPublished • loading... • Updated
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines
Positive trial results and industry backing are reviving support for mRNA cancer vaccines after federal cuts and contract cancellations threatened dozens of projects.
- Pancreatic cancer has a low survival rate, with only 1 in 4 patients living a year after diagnosis and 1 in 10 living two years.
- BioNTech, known for creating the Pfizer COVID vaccine, has adapted its mRNA technology for cancer treatments over the past decade.
- After a challenging year, there are positive signs that mRNA vaccine development is progressing well.
- Elizabeth Jaffee expressed excitement over recent early-stage trials, noting numerous successes.
Insights by Ground AI
30 Articles
30 Articles
TVA NouvellesReposted by 
24heures.ca
24heures.caResearchers have developed a personalized mRNA vaccine that has enabled cancer patients to survive beyond prognosis.
·Montreal, Canada
Read Full Article
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines
The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened to slow or derail dozens of potential cancer treatments. Now there are signs that the mRNA train is still on track.
·Atlanta, United States
Read Full ArticleCoverage Details
Total News Sources30
Leaning Left2Leaning Right0Center27Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
